Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

INTRODUCTION: Riociguat, an oral soluble guanylate cyclase stimulator, has been approved for use in adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension. However, there is limited data on its therapeutic use in children. CASE PRESENTATION: We report the...

Descripción completa

Detalles Bibliográficos
Autores principales: Domingo, L. T., Ivy, D. D., Abman, S. H., Grenolds, A. M., MacLean, J. T., Breaux, J. A., Minford, K. J., Frank, B. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751701/
https://www.ncbi.nlm.nih.gov/pubmed/36533232
http://dx.doi.org/10.3389/fped.2022.1014922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751701/
https://www.ncbi.nlm.nih.gov/pubmed/36533232
http://dx.doi.org/10.3389/fped.2022.1014922

Ejemplares similares